Bio-Rad price target raised to $265 from $245 at Wells Fargo

Wells Fargo analyst Brandon Couillard raised the firm’s price target on Bio-Rad (BIO) to $265 from $245 and keeps an Equal Weight rating on the shares. The firm believes shares of Bio-Rad should open higher on the solid Q2 beat and upward guidance revision. Commentary on U.S. academic demand was surprisingly constructive. Overall, a positive step toward “new-ish” management building more credibility with Street, says Wells.